Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on February 13, 2026. The filing discloses an underwritten public offering of ordinary shares entered into on February 12, 2026, with Piper Sandler & Co. The company is based in London and operates in the pharmaceutical sector, focusing on clinical development.
Key Financial Metrics
This filing does not provide historical revenue, profit, cash flow, margins, or debt figures. The primary financial data relates to the proposed capital raise:
- Shares Offered: 10,815,000 ordinary shares.
- Offering Price: $1.85 per share.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 1,622,250 additional shares.
- Gross Proceeds: Approximately $20 million (excluding underwriting discounts, commissions, and offering expenses).
- Use of Proceeds: Clinical development of product candidates, general corporate purposes, and working capital.
Material Changes
The filing does not report material changes to prior period financial results. The significant event is the execution of the Underwriting Agreement for the public offering, with closing expected on February 17, 2026, subject to customary conditions.
Guidance, Outlook, and Risks
Management intends to utilize net proceeds to advance clinical development and support working capital needs. The filing notes that the Underwriting Agreement includes customary representations, warranties, covenants, and indemnification rights. An investor presentation is included as an exhibit but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 17, 2026) and whether the over-allotment option was exercised.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific underwriting discounts and commissions to calculate net proceeds.
- Confirm the specific allocation of funds between clinical development and general corporate purposes in subsequent filings.
- Check for any updates to the company's clinical trial status or product candidate pipeline following the capital raise.